Melanoma Stage Iii clinical trials

Explore recruiting melanoma stage iii clinical trials.

Recruiting melanoma stage iii studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Melanoma Stage Iii trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

SWE-NEO: Swedish NeoAdjuvant Trial Comparing anti-PD-1 Monotherapy to Combined anti-CTLA-4/anti-PD-1 blockade in Resectable Stage III Melanoma

Sweden

Therapeutic confirmatory (Phase III) EU CTIS Study details

NeoLIPA: A multi center phase II open label study of neoadjuvant LTX-315 in combination with pembrolizumab in patients with clinically detectable and resectable stage III-IV melanoma

Norway

Therapeutic exploratory (Phase II) EU CTIS Study details

Open-label, randomized Phase II trial with BNT111 and cemiplimab in combination or as single agents in patients with anti-PD 1/PD-L1-refractory/relapsed, unresectable Stage III or IV melanoma

Spain, Germany, Italy, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

A pivotal Phase III, open-label, randomized, controlled multi-center study of the efficacy of L19IL2/L19TNF neoadjuvant intratumoral treatment followed by surgery versus surgery alone in clinical stage III B/C melanoma patients

Poland, Italy, France, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

An Open-Label, Randomized, Controlled Multi-Center Study of The Efficacy of Daromun (L19IL2 + L19TNF) Neoadjuvant Intratumoral Treatment Followed by Surgery and Adjuvant Therapy Versus Surgery and Adjuvant Therapy in Clinical Stage IIIB/C Melanoma Patients

Spain, Germany, Italy, Sweden

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Study Evaluating Pharmacokinetic Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Stage III and Stage IV Melanoma in the Adjuvant Setting

Italy, Germany, Netherlands, France, Spain, Croatia +2 more

Human Pharmacology (Phase I)- Bioequivalence Study EU CTIS Study details

Melanoma Stage Iii trials by city

Melanoma Stage Iii in Toronto Melanoma Stage Iii in Vancouver Melanoma Stage Iii in Montreal Melanoma Stage Iii in Calgary Melanoma Stage Iii in Edmonton Melanoma Stage Iii in Ottawa Melanoma Stage Iii in Winnipeg Melanoma Stage Iii in Quebec City Melanoma Stage Iii in Hamilton Melanoma Stage Iii in Kitchener Melanoma Stage Iii in London Melanoma Stage Iii in Halifax Melanoma Stage Iii in New York Melanoma Stage Iii in Los Angeles Melanoma Stage Iii in Chicago Melanoma Stage Iii in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease